Compare ICCM & EOCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ICCM | EOCN |
|---|---|---|
| Founded | 2006 | 2000 |
| Country | Israel | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6M | 2.9M |
| IPO Year | 2013 | 2013 |
| Metric | ICCM | EOCN |
|---|---|---|
| Price | $0.77 | $2.10 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $22.67 | N/A |
| AVG Volume (30 Days) | ★ 118.4K | 6.1K |
| Earning Date | 11-23-2026 | 11-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $27.11 | N/A |
| Revenue Next Year | $104.97 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.13 | $2.30 |
| 52 Week High | $9.54 | $3.80 |
| Indicator | ICCM | EOCN |
|---|---|---|
| Relative Strength Index (RSI) | 28.77 | 32.26 |
| Support Level | $0.22 | $2.32 |
| Resistance Level | $2.50 | $3.48 |
| Average True Range (ATR) | 0.10 | 0.30 |
| MACD | 0.02 | -0.04 |
| Stochastic Oscillator | 25.02 | 23.09 |
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
Eocene Ltd is a GI-focused medtech and biopharmaceutical company focused on advancing solutions across gastrointestinal disease management, GI oncology and related therapeutic areas. Its wholly owned subsidiary develops medical devices for postoperative colorectal care, including CG-100, an intraluminal bypass device intended to protect colorectal anastomoses and reduce the need for diverting stomas. The company's therapeutic portfolio includes Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule being evaluated in liver disease and oncology indications, including gastrointestinal cancers.